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ABSTRACT  
Objectives 
Bell’s palsy (BP), which causes facial paralysis, affects 11-40 people per 100,000 
per annum in the UK. Its cause is unknown but as many as 30% of patients have 
continuing facial disfigurement, psychological difficulties and occasionally facial 
pain. We present a RCT based economic evaluation of the early administration of 
steroids (prednisolone) and/or antivirals (acyclovir) compared to placebo, for 
treatment of BP. 
Methods 
The RCT was not powered to detect differences in the cost-effectiveness (CEA); 
therefore, we adopted a decision analytic model approach as a way of gaining 
precision in our CEA comparisons (e.g. prednisolone only (PO) vs. acyclovir only 
vs. prednisolone and acyclovir vs. placebo; prednisolone vs. no prednisolone 
(NP) and acyclovir vs. no acyclovir (NA)). We assumed that trial interventions 
affect the probability of being cured/not cured but their consequences are 
independent of the initial therapy. We used the percentage of individuals with a 
complete recovery (based on House-Brackmann grade=1) at 9 months and 
QALYs (e.g. derived on responses to the Health Utilities Index 3) as measures of 
effectiveness. Other parameter estimates were obtained from trial data.  
Results  
PO dominated -i.e. was less costly and more effective- all other therapy strategies 
in the four arms model (77% probability of CE). Moreover, Prednisolone 
dominated  NP (77% probability of being cost effective (CE) at £30,000 threshold) 
while NA dominated aciclovir (85% chance of CE), in the two arms models, 
respectively.   
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Conclusions 
Treatment of BP with prednisolone is likely to be considered cost-effective while 
treatment with aciclovir is highly unlikely to be considered cost-effective.  
Further data on costs and utilities would be useful to confirm findings. 
KEYWORDS  
Economic evaluation, Bell’s Palsy, Prednisolone, Acyclovir, cost effectiveness 
analysis, cost utility analysis.  
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Introduction  
Bell’s palsy is an acute unilateral paralysis of the facial nerve.(1) Its cause is 
unknown but it affects 11-40 people per 100,000 in the population per annum, 
most commonly in the age group 30–45.(2) The condition is most common 
amongst pregnant women and people who have diabetes, influenza, a cold, or 
some other upper respiratory ailment. Although most recover, as many as 30% of 
people have a poor recovery with continuing facial disfigurement, psychological 
difficulties and sometimes facial pain.(2-4) In the absence of an established 
aetiology, treatment continues to be based upon the established pathophysiology: 
swelling and entrapment of the nerve. 
 
Two Cochrane reviews have examined the effectiveness of oral prednisolone and 
aciclovir for the treatment of Bell's palsy (5, 6) and both report insuffient evidence 
on the effectiveness.  In addition, high dose steroid therapy has numerous 
potential side effects including peptic ulceration, hypertension and confusional 
states.(7) Antiviral therapy is expensive and it has been argued should be 
reserved for circumstances where definite benefits are likely to be obtained.  
 
Given this lack of evidence the UK NHS R&D Health Technology Assessment 
Programme commissioned a RCT to determine whether prednisolone or 
aciclovir, used separately or in combination and used early in the course of Bell’s 
palsy, is an effective and efficient treatment.  The aim of this paper is to report 
evidence on the relative efficiency of these therapies.   
 
3 Methods 
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Details of the RCT have been reported elsewhere.(8)  Briefly, this was a multi-
centre, double-blind, placebo controlled, randomised, factorial trial involving 
patients with Bell’s palsy who were recruited within 72 hours after onset of 
symptoms.  Five hundred and fifty one patients were recruited from primary 
care settings and referred to 17 hospitals in Scotland between June 2004 and June 
2006, where eligible patients were randomly assigned to receive 10 days of 
treatment of: 25mg twice daily with prednisolone (n=138), or 400mg five times 
daily with acyclovir (n=138), both agents (n=134), or placebo (n=141). Follow-up 
was 9 months. The primary outcome was complete recovery of facial function as 
rated on the House-Brackmann scale. Secondary outcomes included quality of 
life, appearance, pain, costs and relative efficiency.  The study included adults of 
16 years or older with unilateral facial weakness of no identifiable cause who 
presented to primary care or emergency department and could be referred to a 
collaborating otorhinolaryngologist within 72 hours of the onset of symptoms. 
Exclusion criteria were pregnancy, breast-feeding, diabetes, peptic ulcer disease, 
suppurative otitis media, herpes zoster, multiple sclerosis, systemic infection, 
sarcoidosis and other rare conditions, and an inability to provide informed 
consent. All participants gave written informed consent. The study was 
approved by the Multicentre Research Ethics Committee for Scotland. 
 
The economic evaluation conducted as part of this trial adopted a modelling 
approach as a means of gaining precision in cost-effectiveness estimates. Decision 
analytic models were constructed to compare the relative efficiency of the four 
randomised arms and also for the 2 randomised comparisons from the 2x2 
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factorial design: prednisolone against no prednisolone and aciclovir against no 
aciclovir.  As the time horizon of the economic analyses mirrors that of the 
original study, we believe this type of model gives a well representation of the 
decision problem.  An example of the model structure is shown in Figure 1a. 
Within these models it is assumed that the different trial interventions affect the 
probability of being cured or not cured and the consequences are assumed to be 
independent of the assigned therapy.   
 
3.1 Parameter estimates used in the model 
Parameter estimates for probabilities, costs and effectiveness required to 
populate the model were developed from trial data. These data related to risk of 
being cured or not cured at different time points, health services resource use and 
costs and health state utilities. 
 
3.1.1 Probability of cure and not cure 
Table 1 shows the proportion of subjects cured and not cured at three and nine 
months, used as probabilities within the model.  Normal probability distributions 
were attached to the difference in proportions between groups to allow for 
parameter uncertainty.   
 
3.1.2 Health care resource use and costs 
The costs estimates used in the model were based on the cost of the initial 
treatments and follow-up costs.  Follow-up costs included the use of resources in 
primary and secondary care, and the subsequent use of other medications.  These 
resources were costed using readily available unit costs.  
 
Hernández et al. 
10 
Treatment costs 
The doses and length of treatment for trial medications were defined by the trial 
protocol. The unit costs were obtained from British National Formulary (BNF)(9), 
(Table 2a). 
 
Follow-up costs 
Primary and secondary care resource use 
Health Care resources used were collected from primary care case notes in a 
convenience sample of 74 study subjects on any contacts made with health 
services or resources used by trial participants. This sub-sample appears 
representative of the whole study sample (see website Suplementary Data for 
details of baseline characteristics). The number of contacts are described in Table 
2b split by whether the data referred to cured or not cured patients (see website 
Supplementary Data for further details on Resource Use). Hospital based services 
(inpatient days, day cases, and outpatient visits) were costed using data from the 
Information Services Department (ISD) for Scotland(10) after deducting 
overheads allocated to the particular cost category (see website Supplementary 
Data).  Unit cost for primary care based services were obtained from Curtis & 
Netten 2006 (11) and from the BNF for medications.(9)  
 
Total Costs 
Using all the data described above estimates of the total mean costs for those 
cured and not cured were estimated (Table 2b).  A simple ordinary least squared 
(OLS) regression was fitted to the data obtained from those people for whom 
data were able to be collected (n=74).  The total mean values used within the 
Economic Evaluation of Bell’s Palsy early treatment 
11 
model were £210 (s.e. 58) for cured with not cured being £105 (s.e. 112) more 
costly at three months.  Normal distributions were added to the total cost of 
being cured and not cured with the total cost of not cured bounded at zero 
within the probabilistic sensitivity analysis. 
 
3.1.3 Estimation of utilities 
The RCT (8) collected data on Health Utilities Index mark III (HUI III) (12) at 
baseline, three months and, if trial participants were not cured at three months, 
also at nine months.  Two analyses of covariance adjusting for baseline HUI III 
scores were used to obtain utility weights for participants who were cured and 
not cured at three and nine months (Table 3). In order to reflect the statistical 
imprecision surrounding these estimates when used in the model, normal 
distributions were attached to the mean difference in values based upon the 
results of a regression analysis.  
 
Base case analysis 
Base case analysis was conducted for all four randomised arms (e.g. four arms 
model).  Secondary analyses comparing prednisolone vs. no prednisolone and 
aciclovir vs. no aciclovir were also conducted.  For all analyses cumulative mean 
costs were estimated for the nine months follow-up period of the trial.  All costs 
were expressed in 2006/07 pounds Sterling.  The perspective of the analyses was 
that of the British National Health Service.  Effectiveness was measured in terms 
of number of cases cured (e.g. House-Brackmann score = 1), and mean QALYs 
for the nine month time horizon.  As the time horizon for the analyses was less 
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than a year, neither cost nor effectiveness outcomes were discounted.  
Incremental cost effectiveness ratios (ICER) were calculated.   
 
Sensitivity analysis 
Deterministic and probabilistic sensitivity analyses were conducted. The latter 
involved attaching probability distributions to the model parameters and 
conducting Monte Carlo simulations (MCS). One thousand iterations were 
obtained for each MCS conducted.  These MCS were used to produce cost-
effectiveness acceptability curves (CEACs) –Figure 2a- from which the likelihood 
of an intervention being considered cost-effective for society’s willingness to pay 
at threshold values of £10,000, £20,000, £30,000 and £50,000 were calculated 
(Table 4) and cost-effectiveness scatterplots (Figure 2b & 2c).  CEACs for the two 
arms models are reported as website Supplementary Data. 
 
Further sensitivity analyses related to changes in key parameters used in the 
model e.g. unit cost values or to changes in model assumptions relating to the 
derivation of cost and the definition of cure.  Cost data are typically skewed to 
the right as there are usually a few trial participants for which costs are extremely 
high. A sensitivity analysis was conducted taking these potential outliers out of 
the analysis.   
 
Potential drivers in these models are the probability of being cured or not cured 
at three months; therefore, threshold analysis was also used to explore the effect 
of the probability of being cured or not cured on the model results.  In addition, 
subgroup analyses by age and sex were also performed.  Finally, structural 
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uncertainty was explored by assuming an exponential regression and gamma 
regression (together with gamma distributions for Monte Carlo simulations) 
analyses for total costs instead of the original ordinary least squared regression. 
 
4 Results  
4.1 Comparison of all four randomised groups 
On average, prednisolone only is the least costly and most effective of the four 
alternative interventions (Table 4). Furthermore, it has approximately an 80% 
chance of being considered cost-effective compared with the other treatments 
(Figure 2a & Table 4).  
 
4.2 Prednisolone vs. no prednisolone model 
When the proportion of cases cured (Cost-effectiveness analysis) or QALYs 
(Cost-utility analysis) are used as the measure of effectiveness prednisolone has a 
lower mean cost and is more effective than the no prednisolone alternative (Table 
4).  Thus, prednisolone dominates the ‘no prednisolone intervention.  Table 4 also 
shows that prednisolone is likely to be considered a cost-effective treatment at all 
values for society’s willingness to pay for a QALY. Figure 2b shows the cost-
effectiveness scatterplot. The majority of the Monte Carlo simulation cost 
effectiveness result dots lay within the sout east quadrant and for these 
prednisolone treatment is more effective and less costly than no prednisolone 
treatment. 
 
4.3 Aciclovir vs. no aciclovir model 
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Table 4 shows the incremental cost per case cured and per QALY for the 
comparison of aciclovir with no aciclovir.  The no aciclovir alternative has on 
average lower costs and a higher proportion of individuals recovered.  Therefore, 
on average no aciclovir dominates aciclovir treatment. The probabilistic analysis 
reinforces this finding (Table 4 and Figure 2c). 
 
4.4 Sensitivity analysis 
A wide range of sensitivity analyses were conducted. Results were not sensitive 
to the exclusion of the higher cost participants from the analysis, to halving or 
doubling the unit costs, or when an exponential regression was used to estimate 
total cost for cured or not cured participants to allow the right skew for the cost 
data. Prednisolone only appeared less likely to be considered cost-effective when 
gamma regression and gamma distributions were used. 
 
One-way sensitivity analyses were conducted on the difference in the probability 
of being cured at three months. The 95%CI upper and lower limits for the 
difference in cure rates were used for this (Table 1). Cost-effectiveness or cost-
utility analyses results were not sensitive to these changes for prednisolone vs. 
no prednisone model.  
 
However, results were sensitive to the probability of being cured at three months 
within the aciclovir vs. no aciclovir model. When the difference in the probability 
of being cured at three months between the aciclovir arm and no aciclovir arm 
was 3.3% (the upper limit of the 95%CI), the ICER was £9,576.  Further threshold 
analyses were conducted and ICERs of about £20,000 and £30,000 were obtained 
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for 2% and 1.5% differences in the absolute probability of cure, respectively.  
Therefore, the confidence interval surrounding the difference in cure rates 
between aciclovir arm and no aciclovir arm is sufficiently wide to contain 
clinically and economically important differences.   
 
Age group and gender 
Regression analyses for total cost and for utility weights show age group 
variables as well as gender were statistically non-significant. Given these data no 
estimates of incremental cost per QALY were estimated for different age groups 
or by gender. 
 
4 Discussion 
The results of the economic evaluation suggest that the use of prednisolone is 
likely to be considered cost-effective.  Aciclovir, in contrast, appears to be on 
average no more effective but more costly than no treatment or treatment with 
prednisolone.  Thus, it is unlikely to be considered cost-effective.  The time 
horizon of the model was only nine months.  Therefore, an implicit assumption is 
that there are no further benefits and cost savings from the use of prednisolone 
after the end of the time horizon.  Given the difference in cure rates that existed 
at nine months it is possible that should the time horizon be extended treatment 
of Bell’s palsy with prednisolone would be associated with further gains in 
quality of life.  Furthermore, it is likely that those who did not receive 
prednisolone would make more use of health services; thus, increasing their cost 
relative to those who received prednisolone. 
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The economic analysis used a modelling framework to estimate relative 
efficiency.  This approach has the advantage of making the best use of the limited 
data available but it made the assumption that the main determinant of relative 
efficiency is whether or not the Bell’s palsy was cured or not.   If a standard trial 
based cost-effectiveness analysis had been conducted it is likely that, on average, 
similar but less precised results would have been obtained.  Furthermore, the 
lack of data on costs and the decision not to follow-up those deemed cured at 
three months would have necessitated similar assumptions being made in order 
to handle the missing cost and utilities data(13).   
 
The data on costs used within the model came from a sample of only 74 of the 
trial participants.  This led to a reduction in the precision of the estimates.   
Efforts were made to obtain data from more trial participants but these efforts 
were hampered by the fact that some general practices refused permission to 
view notes even though the participant had granted permission for their records 
to be reviewed.  This appeared to be caused by uncertainty over whether the 
prior consent to view notes would still apply several months after initial 
recruitment of the participant and also the inconvenience of allowing 
investigators access to the practice Despite this limitation these data appear 
representative of the whole sample and the reasons for non-response were 
unconnected to the therapy the participant received or their outcomes (see 
additional web tables 1a & 1b).  With respect to the estimation of QALYs 
measurements of health state utilities were censored for those trial participants 
who were judged to be cured at the three month follow-up.  Therefore an 
assumption was made within the modelling exercise that was tantamount to 
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imputing utility data using the ‘last value carried forward’ method.  Ordinarily 
this approach while simple is normally considered to be a limited method of 
imputation.(14, 15)  However, in this situation it may not be wholly unrealistic as 
these trial participants were judged to be cured at the time of censoring.  
Nevertheless, it assumes that there is no possible further improvement in health 
status for these people nor is there any possibility of relapse.  This latter situation 
is clinically implausible unless there is an unrelated new episode of Bell’s palsy.  
The results of the economic evaluation would have been strengthened by further 
data on both costs and health state utilities.   
 
Within the model the results are driven by the probability of being cured at three 
months and to a lesser extent, the probability of being cured at nine months.  
Both probabilistic and deterministic sensitivity analyses were conducted.  The 
probabilistic sensitivity analysis focused on the statistical imprecision 
surrounding the model parameters using parameter distributions that were 
plausible and based upon the available data.  Further deterministic sensitivity 
analysis was conducted to address uncertainty in the model structure or 
uncertainty surrounding model parameters that were obtained from outwit the 
RCT.  The results of these sensitivity analyses indicate that conclusions are only 
sensitive to assumptions on the probability of being cured for the aciclovir vs. no 
aciclovir model. 
 
Conclusions  
Overall, based on the data available it appears that treatment of Bell’s palsy with 
prednisolone is likely to be considered cost-effective while treatment with 
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aciclovir is highly unlikely to be considered cost-effective.  Given the limited data 
available on costs and utilities further data would be useful to confirm findings.  
Similarly even though it is unlikely to change conclusion further data on costs 
and outcomes in the longer term (i.e. for a follow-up greater than nine months) 
would also serve to confirm the findings of the study.  
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Table 1 Probability parameters 
 
Probability being cured at 3 
months 
Probability being cured at 9 
months given not cured at 3 
months 
Four arms model   
Prednisolone alone 0.84 0.71 
(s.e.) (0.03) (0.11) 
Aciclovir alone 0.60 0.44 
(s.e.) (0.04) (0.07) 
Aciclovir & prednisolone 0.78 0.68 
(s.e.) (0.04) (0.09) 
Placebo alone 0.65 0.57 
(s.e.) (0.04) (0.08) 
Prednisolone vs. no prednisolone 
 
  
Prednisolone 0.83 0.49 
No prednisolone 0.64 0.61 
Difference (95% CIs) 0.19 (0.12 , 0.27)  
PD* Assumed for difference Normal  
Aciclovir vs. no aciclovir model 
Aciclovir 0.71 0.49 
No acyclovir 0.76 0.61 
Difference (95% CIs) -0.05 (-0.12 , 0.03)  
PD Assumed for difference Normal  
* PD = probability distribution  
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Table 2a Resource use and costs: drug treatment 
Drug Dose Cost Note BNF WebPage * 
Prednisolone 50mg/day x 10d 4.32 
Prednisolone 
Tablets, 25 mg, 56-tab pack = £12.09 http://www.bnf.org/bnf/bnf/53/4259.htm 
Aciclovir 2000mg/day x 10d. 6.57 
Aciclovir 
Tablets, 400 mg, 56-tab pack = £7.31; 800 mg, 
35-tab pack = £9.22 http://www.bnf.org/bnf/bnf/53/37356.htm 
* Accessed: 21st May 2007 
 
Table 2b Resource use and costs: Health care resource use by main cost categories. Cured or not cured patients 
 Cured at three months Cured at nine months Not cured 
Concept 
Primary 
Care 
(contacts) 
Hospital 
(inpatient 
days & day 
cases) 
Hospital 
Outpatient 
(visits) 
Primary 
Care 
(contacts) 
Hospital 
(inpatient 
days & day 
cases) 
Hospital 
Outpatient 
(visits) 
Primary 
Care 
(contacts) 
Hospital 
(inpatient 
days & day 
cases) 
Hospital 
Outpatient 
(visits) 
N 52 53 51 11 11 10 9 9 9 
Mean (s.d.) 2.15 (3.9) 0.11 (0.38) 0.49 (1.17) 3.82 (3.68) 0.09 (0.3) 1.8 (2.62) 3.22 (2.73) 0 (0) 1.22 (1.56) 
Median [IQR] 1 [0 - 2] 0 [0 - 0] 0 [0 - 1] 3 [1 - 5] 0 [0 - 0] 0.5 [0 - 3] 3 [2 - 3] 0 [0 - 0] 1 [0 - 1] 
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Table 3 HUI III regression analysis for three and nine months cured and not cured utility weights 
Dependent variable: HUI III at three months 
Number of obs = 487    
 Coefficient Std. Err. [95% Conf. Interval] 
Constant 0.6146 0.0235 0.5684 0.6609 
hb3cured 0.0574 0.0132 0.0314 0.0834 
Dependent variable: HUI III at nine months 
Number of obs = 137    
 Coefficient Std. Err. [95% Conf. Interval] 
Constant 0.5265 0.0495 0.4287 0.6243 
Cured -0.0019 0.0293 -0.0599 0.0561 
 Utility weights (mean values) 
Cured at 3 
months 
Cured at 9 
months  Not cured  
0.9947 0.9900  0.9919  
Baseline characteristics. HUI III data All participants 
Mean: 0.786 sd 0.216  
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Table 4 Cost-effectiveness results 
Treatment Cost (£) 
Cured cases* 
at 9 months 
(%) 
 ICER** QALYs ICER*** 
Probability that intervention is cost-
effective for different threshold values 
for society’s willingness to pay for a 
QALY (%) 
      £10,000 £20,000 £30,000 £50,000 
Four arms model 
Prednisolone only 182.34 85.6%  0.719  79.1% 77.4% 76.9% 75.9% 
Aciclovir + Prednisolone 198.09 78.0% Dominated 0.718 Dominated 0.0% 0.0% 0.0% 0.1% 
No treatment 205.14 78.0% Dominated 0.717 Dominated 12.5% 9.5% 7.2% 5.2% 
Aciclovir only 219.62 78.0% Dominated 0.716 Dominated 8.4% 13.1% 15.9% 18.8% 
Prednisolone vs. No prednisolone model 
Prednisolone 231.98 94.4%  0.718  79.3% 77.5% 77.0% 76.0% 
No Prednisolone 248.05 81.6% dominated 0.717 Dominated 20.7% 22.5% 23.0% 24.0% 
Aciclovir vs. No aciclovir model 
No Aciclovir 235.33 90.8%  0.718  91.1% 85.1% 82.2% 79.0% 
Aciclovir 246.63 85.4% dominated 0.717 Dominated 8.9% 14.9% 17.8% 21.0% 
* Cured cases defined as HB score = 1; ** Incremental cost effectiveness ratio using % cured cases; ***Incremental cost effectiveness ratio using QALYs 
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Figure 1a Decision tree model for early treatment for Bells palsy: Prednisolone 
alone vs. aciclovir alone vs. prednisolone + aciclovir vs. no treatment 
(placebo) 
Prednisolone
No treatment
Prednisolone + Aciclovir
Aciclovir
Identical Sub-tree structures for all 
decision branches
Cured at 3 m.
Not cured at 3 m.
Cured at 9 m.
Not cured at 9 m.
Estimated
costs and effects for:
Cured at 3 m.
Cured at 9 m.
Not cured
 
Figure 1a. The four decision branches reflect the four groups provided by the 2 x 2 factorial 
trial design. It has been assumed that the costs consequences of being cured or not cured are 
independent of the initial treatment a person was allocated to. 
 
 
Figure 1b Bell's palsy decision tree model: Prednisolone vs. no prednisolone  
Prednisolone
No prednisolone
Cured at 3 months
Not cured at 3 months
Cured at 9 months
Not cured at 9 months
Estimated
costs and effects for:
Cured at 3 months
Cured at 9 months
Not cured
Cured at 3 months
Not cured at 3 months
Cured at 9 months
Not cured at 9 months
Cured at 3 months
Cured at 9 months
Not cured
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Figure 2a Cost-effectiveness acceptability curves. Four arms model. 
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These CEACs indicate that collectively the other interventions have only a 20% chance of 
being considered cost-effective.  
 
Figure 2b Incremental cost effectiveness scatterplot. Prednisolone vs. No 
prednisolone model. 
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Figure 2b. Scatterplot of the difference in cost and QALY pairs for the comparison of 
prednisolone compared with no prednisolone from the Monte Carlo simulation.  A high 
proportion of the dots are allocated within the SE quadrant. Therefore, for those cases, 
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prednisolone produced more QALYs and was less costly than no prednisolone and 
prednisolone is cost-effective for these iterations.  The opposite argument applies to those 
cases that fall within the NW quadrant (e.g. no prednisolone option is cost-effective).  
Finally, for those iterations that fall within the NE and SW quadrants the decision for or 
against prednisolone will depend on threshold value of WTP for an extra QALY.  
 
Figure 2c Incremental cost effectiveness scatterplot. Aciclovir vs. No aciclovir model. 
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Figure 2c. Scatterplot of the incremental cost and QALY pairs from the Monte Carlo 
simulation shows that the majority of the iterations lie within the NW quadrant (e.g. 
aciclovir more costly and less effective that no aciclovir). 
 
 
